康莱特注射液联合吉非替尼治疗EGFR阳性中晚期非小细胞肺癌的临床观察

Clinical Observation of Kanglaite Injection Combined with Gefitinib in the Treatment of Non-small Cell Lung Cancer with EGFR Positive in Medium or Late Stage

目的：研究康莱特注射液联合吉非替尼治疗EGFR阳性中晚期非小细胞肺癌的疗效。方法：将45例中晚期非小细胞肺癌患者随机分为联合靶向组及单纯靶向组，联合靶向组采用康莱特注射液联合吉非替尼口服治疗，单纯靶向组采用吉非替尼口服治疗，观察两个疗程后评价疗效。结果：联合靶向组总有效率56．0％，高于单纯靶向组的40．0％（P〈0．05）；在生活质量方面，联合靶向组的总有效率84．0％，高于单纯靶向组的60．0％（P〈0．05）。结论：康莱特注射液联合吉非替尼治疗EGFR阳性中晚期非小细胞肺癌的疗效优于单纯口服吉非替尼，同时生活质量明显改善，是，临床治疗EGFR阳性中晚期非小细胞肺癌有效的治疗方法。

Objective： Study on effect of Kanglaite injection combined with Gefitinib in the treatment of nonsmall cell lung cancer with EGFR positive in medium or late stage. Methods： 45 cases of medium and advanced nosmall cell lung cancer were randomly divided into combined target group and simple target group, combined target group was given Kanglaite injection combined with Ge fitinib PO, while simple targeting group given Gefitinib PO, for evaluation of curative effect after two courses. Results： Total effec tive rate of combined target group was 56% ,higher than the simple targeted group of 40% （P〈0.05）; In terms of life quality, total ef fective rate of combined target group was 84%, higher than the targeted group of 60% （P〈0.05）. Conclusion： the curative effect of Kanglaite injection combined with Kyrgyzstan in the treatment of medium and advanced nonsmall cell lung cancer with EGFR posi tive is better than Gefitinib PO , at the same time, improved quality of life, is the effective clinical treatment for medium and ad vanced nonsmall cell lung cancer with EGFR positive.